NCT02574663View on ClinicalTrials.gov

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 11, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions

Pancreatic CancerColorectal CancerRectal CancerGastric CancerEsophageal CancerGastrointestinal Stromal Tumor (GIST)

Interventions

DRUG

TGR-1202

TGR-1202 oral daily dose

DRUG

nab-paclitaxel + gemcitabine

IV infusion

DRUG

Oxaliplatin + Folinic acid + Fluorouracil

IV infusion

DRUG

Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab

IV Infusion

Trial Locations (1)

37203

TG Therapeutics Trial Site, Nashville

All Listed Sponsors

collaborator

SCRI Development Innovations, LLC

OTHER

lead

TG Therapeutics, Inc.

INDUSTRY

NCT02574663 - TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter